Viral Load for HIV Treatment Failure Management: A Report of Eight Drug-Resistant Tuberculosis Cases Co-Infected with HIV Requiring Second-Line Antiretroviral Treatment in Mumbai, India

Andries, Aristomo; Das, Mrinalini; Isaakidis, Petros; Saranchuk, Peter

doi:10.4269/ajtmh.13-0526

Cited by 1 publication

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six articles, four cohort studies [ 14 – 17 ] and two case series [ 13 , 18 ], met the inclusion criteria. These studies include MDR/RR-TB and HIV co-infected patients treated between 2008 and 2013, and all patients were treated with standard, not short course, injectable MDR/RR-TB regimens.…”

Section: Resultsmentioning

confidence: 99%

“…These studies include MDR/RR-TB and HIV co-infected patients treated between 2008 and 2013, and all patients were treated with standard, not short course, injectable MDR/RR-TB regimens. Only four of the included articles, including the two case series, reported the ART regimens used to treat MDR/RR-TB and HIV co-infected patients during the study period [ 13 – 15 , 18 ]. These articles noted that ART regimens were aligned with national guidelines and first-line regimens included the.…”

Section: Resultsmentioning

confidence: 99%

“…These articles noted that ART regimens were aligned with national guidelines and first-line regimens included the. medications tenofovir, stavudine, lamivudine, zidovudine with efavirenz [ 13 – 15 , 18 ] Given the small number of patients and the types of cases described in the case series manuscripts, these two articles contribute little to answer the questions posed in this review and are discussed separately. The remaining four articles reported two HIV disease-specific indicators: CD4 cell count [ 14 , 15 , 17 ] and viral load [ 14 – 16 ].…”

Section: Resultsmentioning

confidence: 99%

“…Two articles that met inclusion criteria were case series [ 13 , 18 ]. Both focused on MDR/RR-TB and HIV co-infected patients who were diagnosed with virologic failure and changed from first- to second-line ART during the period of MDR/RR-TB treatment.…”

Section: Resultsmentioning

confidence: 99%

“…No discrepancies remained after discussion. The six remaining articles were assessed for quality using the Johanna Briggs Institute critical appraisal tools [ 13 – 19 ]. Fig 1 details the search results according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

The effects of MDR/RR-TB treatment on HIV disease: A systematic review of literature

2021

View full text Add to dashboard Cite

Background Multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) and human immunodeficiency virus (HIV) co-infection are a deadly combination. While evidence on the effects of HIV co-infection on MDR/RR-TB treatment outcomes is well-documented, little published evidence describes the effects of MDR/RR-TB treatment on HIV disease. Methods We conducted a review of literature published prior to June 2020. We searched Pubmed, CINAHL, and EMBASE using variations of the terms “multidrug-resistant tuberculosis,” “HIV,” and either “CD4” or “viral load.” Two reviewers independently completed title and abstract screening, full-text screening, article evaluation, and data extraction. We also included five published articles evaluated as evidence by the World Health Organization (WHO) in preparation for the 2019 MDR/RR-TB treatment guideline update. Results A total of 459 references were returned, with 362 remaining after duplicate removal. Following article screening, six manuscripts were included. Articles reported CD4 count and/or viral load results for MDR/RR-TB and HIV co-infected patients during and/or after MDR/RR-TB treatment. The additional five references identified from the WHO guideline revision did not report HIV disease indicators after MDR/RR-TB initiation. Conclusion There is a paucity of evidence on HIV disease indicators following MDR/RR-TB treatment. Researchers should report longitudinal HIV disease indicators in co-infected patients in publications.

show abstract